6-month individualized hybrid adapted physical activity program for people with multiple myeloma
Official title: Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma: a Multicenter Randomized Controlled Trial
Run by Centre Hospitalier Metropole Savoie · NCT07547007 · Data updated 2026-11-12
This trial will test whether a 6-month individualized program of adapted physical activity, mixing remote home sessions and in-person hospital sessions, can improve quality of life for people over 60 treated for multiple myeloma who are not eligible for transplant.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 61 Years and up |
| Sex | All |
| Enrollment | 86 (estimated) |
| Sponsor | Centre Hospitalier Metropole Savoie Academic / other |
| Locations | 2 sites (Annecy and 1 other locations) |
| Status | Recruiting |
| Started | January 22, 2026 |
| Main results expected | July 2028 |
| Study ends | July 30, 2028 |
| Registry record updated | April 23, 2026 |
| Trial ID | NCT07547007 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are French-speaking patients over 60 with newly diagnosed or relapsed multiple myeloma (1st–4th line) not eligible for transplant who began systemic treatment within the last three months and can attend periodic hospital visits and remote sessions.
✕Probably not a fit
Patients with conditions that make exercise unsafe (for example severe cardiac amyloidosis or an absolute contraindication to physical activity), those unable to comply with protocol requirements, non–French speakers, or pregnant/lactating women are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants are randomized to either a control group that receives advice about physical activity or an interventional group offered a 6-month individualized adapted physical activity program combining remote (home) and in-person hospital sessions. The study measures quality of life as the main outcome and also tracks effort tolerance, pain, muscle mass, osteolytic lesions, treatment tolerance, and treatment response. Eligible patients are those aged over 60 with newly diagnosed or relapsed multiple myeloma (1st to 4th line) who started systemic treatment within the last three months and have scheduled hospital visits as required. The program is delivered at two regional hospitals in France and requires participants to be able to follow protocol procedures and speak French.
Why it matters
Potential benefit: If successful, the program could improve quality of life, increase physical function, reduce pain, and help patients better tolerate multiple myeloma treatments.
How similar studies have gone: Exercise and adapted physical activity programs have improved quality of life and function in many cancer populations, but long-term individualized hybrid programs specifically in multiple myeloma have been less extensively studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * newly diagnosed or relapse multiple myeloma, \> 60 yo, not eligible to transplant * 1st to 4th line of treatment initiated during the last 3 months * receiving a systemic treatment that involved visit to the hospital at least twice a month durig the first 3 months and at least once a month the next 3 months Exclusion Criteria: * severe cardiac amyloidosis * absolute contraindication to physical activity * inability to comply with the protocol requirements * not french speaker * patient under guardianship or curatorship * pregnant or lactating women
Where it's running
-
CH Annecy Genevois
Annecy, France Recruiting -
CH Métropole Savoie
Chambéry, France Recruiting
Study contacts
- Study coordinator: Charlene DUPRE
- Email: charlene.dupre@ch-metropole-savoie.fr
- Phone: +33479965910
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cognitive changes after BCMA CAR-T in multiple myeloma
This study tests whether cognitive function changes over time in adults with relapsed or refractory multiple myeloma who receive BCMA CAR-T therapy.
-
GPRC5D-targeted PET/CT imaging in plasma cell disorders
This study tests a new GPRC5D-targeted PET/CT imaging method in adults with plasma cell disorders to see if it detects disease better or differently than standard imaging.
-
Gustabor: Tailored AI Nutrition for Taste Changes During Cancer Therapy
This trial tests whether personalized, AI-assisted dietary advice helps people with taste changes from cancer treatment compare to general dietary guidance.
-
Personalising Myeloma Treatment Based on Initial Response and Fitness
This trial tests whether adjusting treatment after six months of the standard DRd therapy, based on a patient’s response and fitness, can improve outcomes for older, transplant-ineligible patients with myeloma.
-
Elranatamab given as outpatient in relapsed or refractory multiple myeloma
This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.
-
CM336 with Isatuximab for Newly Diagnosed Myeloma with Kidney Impairment
This study tests a CM336 and isatuximab regimen in adults with newly diagnosed multiple myeloma and kidney trouble to see if it helps.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.